Free tool
FAERS Monitor: Voquezna
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 215151 or its brand name (Voquezna, Vonoprazan Fumarate). Reports on generic versions are filed under their own applications.
Reports
8,132
Serious
5,240
64% of reports
Hospitalization
3,206
Death reported
1,069
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- diarrhoea526
- off label use520
- nausea485
- drug ineffective457
- gastrooesophageal reflux disease322
- malaise317
- decreased appetite272
- headache271
- pyrexia253
- abdominal pain upper251
- vomiting242
- product dose omission issue232
- illness216
- dizziness214
- dyspnoea214
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 2 |
| 2016 | 17 |
| 2017 | 41 |
| 2018 | 90 |
| 2019 | 119 |
| 2020 | 166 |
| 2021 | 426 |
| 2022 | 807 |
| 2023 | 880 |
| 2024 | 1,448 |
| 2025 | 2,182 |
| 2026 | 1,951 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,046,027 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| gastrooesophageal reflux diseaseSignal | 322 | 10.4 | 9.3 | 2,720 |
| illnessSignal | 216 | 5.4 | 4.8 | 779 |
| abdominal pain upperSignal | 251 | 3.2 | 2.8 | 371 |
| decreased appetiteSignal | 272 | 3.0 | 2.7 | 372 |
| diarrhoeaSignal | 526 | 2.1 | 1.9 | 315 |
| product dose omission issueSignal | 232 | 2.0 | 1.8 | 124 |
| pyrexia | 253 | 1.9 | 1.7 | 107 |
| malaise | 317 | 1.9 | 1.7 | 130 |
| nausea | 485 | 1.6 | 1.5 | 108 |
| off label use | 520 | 1.5 | 1.4 | 101 |
| vomiting | 242 | 1.3 | 1.2 | 20 |
| headache | 271 | 1.1 | 1.0 | 3 |
| dizziness | 214 | 1.1 | 1.0 | 2 |
| dyspnoea | 214 | 1.0 | 0.9 | 0 |
| drug ineffective | 457 | 0.9 | 0.8 | 6 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.